Scandion Oncology announces share purchase by member of management
Scandion Oncology A/S, the Cancer Drug Resistance Company, today announced that a member of management discharging managerial responsibilities has purchased shares in the company.The company’s Chief Operating Officer, Maj Hedtjärn has reported that she has bought 8,000 shares in December 2021. This brings her total shareholding up to 24,000 shares. Persons under an obligation to report are persons discharging managerial responsibilities, as well as persons closely associated with them. For further information please contact: Mads Kronborg, Head of External Communication Phone: